Transcode Therapeutics (RNAZ) Notes Payables (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Notes Payables came in at $652411.0 in Q2 2026, up 1728.25% quarter-over-quarter from $35685.0 in Q4 2021.
Powered by 
Analysis
Transcode Therapeutics (RNAZ) Notes Payables (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has reported Notes Payables for 3 consecutive years, with $652411.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Notes Payables changed N/A year-over-year to $652411.0; the trailing twelve-month figure through Jun 2026 stood at $652411.0 (changed N/A YoY), and the FY2021 full-year result was $35685.0, changed 0.0% from the prior year.
- Notes Payables grew to $652411.0 in Q2 2026 per RNAZ's latest filing, from $35685.0 in the prior quarter.
- Across five years, Notes Payables topped out at $652411.0 in Q2 2026 and bottomed at $652411.0 in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.46 Bn | 192.47 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.92 Bn | 176.75 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.37 Bn | 123.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.86 Bn | 73.87 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.29 Bn | 55.10 Bn | 1.37 Bn |
| 6 | Moderna | 53.76 Bn | 48.62 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.16 Bn | 29.85 Bn | 992.69 Mn |
| 8 | Biogen | 31.90 Bn | 30.62 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.13 Bn | 29.13 Bn | 1.16 Mn |
| 10 | Transcode Therapeutics | 1.70 Mn | 1.70 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 652,411.00 |
| Dec 31, 2021 | 35,685.00 |
| Jun 30, 2021 | 35,525.00 |
| Dec 31, 2020 | 35,685.00 |